{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:10:28Z","timestamp":1790975428432,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Innovative strategies are essential to meet the World Health Organization's 90\/70\/90 cervical cancer elimination targets, aiming for 90% access to precancer treatment globally by 2030. In low-and middle-income countries (LMICs) where most cervical cancer cases occur, access to precancer treatment is severely limited. Scalable solutions like self-administered topical therapies can help close this gap. In a recent Phase I trial (ClinicalTrials.gov NCT05362955), we demonstrated safety and adherence to self-administered intravaginal 5% 5-Fluorouracil (5FU) cream as an adjuvant therapy for cervical precancer among women living with HIV (WLWH) in rural Kenya. To understand women's experiences with self-administered 5FU, we evaluated the acceptability of this intervention among trial participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All 12 participants from the Phase I trial completed a structured questionnaire and in-depth semi-structured interviews in their preferred language, focusing on their experiences with 5FU self-administration, challenges faced, and overall acceptability of the intervention, including whether they would use it again or recommend it to someone who needed it. Quantitative data were analyzed using descriptive statistics. In the qualitative study, acceptability was defined as \u201cthe perception that a given treatment is agreeable, palatable, or satisfactory.\u201d A thematic analysis was conducted using five dimensions of acceptability: content, complexity, comfort, delivery, and credibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 43.9 years (SD 4.4), and seven (58%) had primary education or less. While some participants reported feelings of uncertainty when they started using 5FU, at the end of the study, all 12 participants strongly agreed that the cream was safe and were confident they used it correctly. Most participants (91.7%) experienced no discomfort with the vaginal applicator, and most reported using tampons overnight after 5FU use, as recommended. Qualitative findings revealed that favorable perceptions of self-administered 5FU were driven by its ease of use, the discrete nature of the treatment, and the comfort of home application. The main challenges included correctly measuring the study drug, finding a private place at home to self-administer, and the need to use condoms during treatment. Compared to their previous ablation or excision treatments, participants found 5FU to be less painful, and all would prefer a self-administered treatment instead of a procedure if it were an option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Self-administered intravaginal 5FU as an adjuvant treatment for cervical precancer among women living with HIV in Kenya was highly acceptable. Randomized studies of 5FU and other topical therapies in LMICs are needed to evaluate their use in closing the current precancer treatment gaps in these settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frph.2025.1487264","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:10:58Z","timestamp":1738807858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Women's experiences and acceptability of self-administered, home delivered, intravaginal 5-Fluorouracil cream for cervical precancer treatment in Kenya"],"prefix":"10.3389","volume":"7","author":[{"given":"Konyin","family":"Adewumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna Ghosh","family":"Kachoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everlyn","family":"Adoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Rop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Owaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rahangdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chemtai","family":"Mungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/S2214-109X(18)30533-3","article-title":"Cervical cancer: lessons learned from neglected tropical diseases","volume":"7","author":"Knaul","year":"2019","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1001\/jama.2019.16176","article-title":"Cervical cancer as a global concern: contributions of the dual epidemics of HPV and HIV","volume":"322","author":"Chibwesha","year":"2019","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1700","DOI":"10.1016\/S2214-109X(23)00406-0","article-title":"Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study","volume":"11","author":"Frick","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B5","article-title":"A Global Strategy for elimination of cervical cancer","year":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"key":"B7","unstructured":"WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention\n          \n          2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ijgo.13171","article-title":"Scaling up cervical cancer prevention in Western Kenya: treatment access following a community-based HPV testing approach","volume":"152","author":"Mungo","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ijgo.13485","article-title":"Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africaa","volume":"152","author":"Rohner","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1745506520914804","article-title":"Cervical cancer screening\u2014the challenges of complete pathways of care in low-income countries: focus on Malawi","volume":"16","author":"Cubie","year":"2020","journal-title":"Womens Health (Lond)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-016-3530-y","article-title":"Cervical cancer screening uptake and challenges in Malawi from 2011 to 2015: retrospective cohort study","volume":"16","author":"Msyamboza","year":"2016","journal-title":"BMC Public Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3332\/ECANCER.2022.1442","article-title":"Cervical cancer programme, Kenya, 2011\u20132020: lessons to guide elimination as a public health problem","volume":"16","author":"Mwenda","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijgo.2013.06.035","article-title":"Successes and challenges of establishing a cervical cancer screening and treatment program in western Kenya","volume":"124","author":"Khozaim","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12905-018-0534-Z","article-title":"Predictors of cervical cancer screening intention of HIV-positive women in the central region of Ghana","volume":"18","author":"Ebu","year":"2018","journal-title":"BMC Womens Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2017-016282","article-title":"Knowledge, facilitators and barriers to cervical cancer screening among women in Uganda: a qualitative study","volume":"7","author":"Ndejjo","year":"2017","journal-title":"BMJ Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/BMJOPEN-2015-008533","article-title":"Qualitative study of barriers to cervical cancer screening among Nigerian women","volume":"6","author":"Modibbo","year":"2016","journal-title":"BMJ Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e049901","DOI":"10.1136\/bmjopen-2021-049901","article-title":"Barriers to follow-up after an abnormal cervical cancer screening result and the role of male partners: a qualitative study","volume":"11","author":"Chapola","year":"2021","journal-title":"BMJ Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2024.1371529","article-title":"Baseline assessment of cervical cancer screening and treatment capacity in 25 counties in Kenya, 2022","volume":"14","author":"Mwenda","year":"2024","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.GORE.2020.100608","article-title":"Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2\u20133: a narrative review","volume":"33","author":"Desravines","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ijgo.14983","article-title":"Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2\/3","volume":"163","author":"Desravines","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ygyno.2019.12.035","article-title":"A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"157","author":"Trimble","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ygyno.2023.10.003","article-title":"Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2\/3","volume":"178","author":"Michener","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/AOG.0000000000004384","article-title":"Topical imiquimod for the treatment of high-grade squamous intraepithelial lesions of the cervix: a randomized controlled trial","volume":"137","author":"Fonseca","year":"2021","journal-title":"Obstet Gynecol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijgo.16093","article-title":"Safety and adherence to self-administered intravaginal 5-fluorouracil cream following cervical intraepithelial neoplasia (CIN) 2\/3 treatment among HIV-positive women in Kenya: a phase 1 clinical trial","author":"Mungo","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0295647","article-title":"A phase I study of intra-anal artesunate (suppositories) to treat anal high-grade squamous intraepithelial lesions","volume":"18","author":"Fang","year":"2023","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S0029-7844(99)00407-X","article-title":"Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial","volume":"94","author":"Maiman","year":"1999","journal-title":"Obstet Gynecol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"314.e1","DOI":"10.1016\/j.ajog.2013.12.042","article-title":"Topical 5-flourourcil for treamtent of cervical intraepithelial neoplasia 2: a randomized controlled trial","volume":"210","author":"Rahangdale","year":"2014","journal-title":"Am J Obstetr Gynecol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2022.01.033","article-title":"Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: multicenter, randomized controlled trial","volume":"165","author":"Polterauer","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B29","unstructured":"WHO Model List of Essential Medicines - 23 List,\n          \n          2023"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/archdermatol.2009.291","article-title":"Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review","volume":"145","author":"Love","year":"2009","journal-title":"Arch Dermatol"},{"key":"B31","first-page":"837","article-title":"Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina","volume":"68","author":"Krebs","year":"1986","journal-title":"Obstet Gynecol"},{"key":"B32","first-page":"68","article-title":"Treatment of vaginal condylomata acuminata by weekly topical application of 5-fluorouracil","volume":"70","author":"Krebs","year":"1987","journal-title":"Obstet Gynecol"},{"key":"B33","first-page":"657","article-title":"Treatment of vaginal intraepithelial neoplasia with laser and topical 5-fluorouracil","volume":"73","author":"Krebs","year":"1989","journal-title":"Obstet Gynecol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/AOG.0000000000002311","article-title":"Topical 5-fluorouracil for women with high-grade vaginal intraepithelial neoplasia","volume":"130","author":"Fiascone","year":"2017","journal-title":"Obstet Gynecol"},{"key":"B35","article-title":"UNC Lineberger Comprehensive Cancer Center. Acceptability and feasibility of combination treatment for cervical precancer among South African women living with HIV (ACT2). ClinicalTrials.gov [Internet]. Chapel Hill (NC): UNC Lineberger Comprehensive Cancer Center (2022)","year":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2024.03.11.24304083","article-title":"\u201cARVs is for HIV and cream is for HPV or precancer:\u201d women\u2019s perceptions and perceived acceptability of self-administered topical therapies for cervical precancer treatment: a qualitative study from Kenya","author":"Mungo","year":"2024","journal-title":"medRxiv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1525\/agh.2025.2329438","article-title":"Perceived acceptability of self-administered topical therapy for cervical precancer treatment among women undergoing cervical cancer screening in Kenya","volume":"4","author":"Mungo","year":"2025","journal-title":"Adv Glob Health."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1360337","DOI":"10.3389\/fonc.2024.1360337","article-title":"\u201cThere is nothing that can prevent me from supporting her:\u201d men\u2019s perspectives on their involvement and support of women\u2019s use of topical therapy for cervical precancer treatment in Kenya","volume":"14","author":"Mungo","year":"2024","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3332\/ecancer.2024.1719","article-title":"Men's perceptions and perceived acceptability of their female partner's use of self-administered intravaginal therapies for treatment of cervical precancer in Kenya","volume":"18","author":"Mungo","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2023.12.13.23299916","article-title":"Feasibility of adjuvant self-administered intravaginal 5-fluorouracil cream following primary treatment of cervical intraepithelial neoplasia grade 2 or 3 among women living with HIV in Kenya: study protocol for a pilot trial","author":"Mungo","year":"2023","journal-title":"medRxiv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12905-019-0804-4","article-title":"Female perspectives on male involvement in a human-papillomavirus-based cervical cancer-screening program in western Kenya","volume":"19","author":"Adewumi","year":"2019","journal-title":"BMC Womens Health"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.SSMPH.2021.100773","article-title":"Women\u2019s autonomy in household decision-making and safer sex negotiation in sub-Saharan Africa: an analysis of data from 27 demographic and health surveys","volume":"14","author":"Seidu","year":"2021","journal-title":"SSM Popul Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e26245","DOI":"10.1002\/jia2.26245","article-title":"A sub-national HIV epidemic appraisal in Kenya: a new approach for identifying priority geographies, populations and programmes for optimizing coverage for HIV prevention","volume":"27","author":"Banadakoppa Manjappa","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"B44","article-title":"Kenya National Cancer Screening Guidelines. Published online (2018):1-122","author":"Nairobi","year":""},{"key":"B45","article-title":"Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events.","year":""},{"key":"B46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"B47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/13691051003728599","article-title":"Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India","volume":"12","author":"Greene","year":"2010","journal-title":"Cult Health Sex"},{"key":"B48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.socscimed.2004.05.011","article-title":"Microbicide acceptability research: current approaches and future directions","volume":"60","author":"Mantell","year":"2005","journal-title":"Soc Sci Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10461-005-1687-y","article-title":"A framework for examining the sustained acceptability of microbicides","volume":"9","author":"Severy","year":"2005","journal-title":"AIDS Behav"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s10461-009-9635-x","article-title":"Adherence and its measurement in phase 2\/3 microbicide trials","volume":"14","author":"Tolley","year":"2010","journal-title":"AIDS Behav"},{"key":"B51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4236\/ojog.2013.33058","article-title":"Same day colposcopic examination and loop electrosurgical excision procedure (LEEP) presents minimal overtreatment and averts delay in treatment of cervical intraepithelial neoplasia in Kenyatta National Hospital, Kenya","volume":"3","author":"Kays","year":"2013","journal-title":"Open J Obstet Gynecol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/jama.2019.14969","article-title":"Effect of cryotherapy vs loop electrosurgical excision procedure on cervical disease recurrence among women with HIV and high-grade cervical lesions in Kenya: a randomized clinical trial","volume":"322","author":"Greene","year":"2019","journal-title":"JAMA"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12879-020-05003-9","article-title":"Peer education for HIV prevention among high-risk groups: a systematic review and meta-analysis","volume":"20","author":"He","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2021.10.001","article-title":"Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world","volume":"106","author":"Ridgeway","year":"2022","journal-title":"Contraception"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2022.114133","article-title":"Women\u2019s preferences and acceptance for different drug delivery routes and products","volume":"182","author":"Palmeira-de-Oliveira","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12905-018-0657-2","article-title":"Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories","volume":"18","author":"Zaveri","year":"2018","journal-title":"BMC Womens Health"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0147917","article-title":"A single-arm, proof-of-concept trial of lopimune (lopinavir\/ritonavir) as a treatment for HPV-related Pre-invasive cervical disease","volume":"11","author":"Hampson","year":"2016","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-020-09570-z","article-title":"Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis","volume":"20","author":"Farahmand","year":"2020","journal-title":"BMC Public Health"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2025.1487264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:11:09Z","timestamp":1738807869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2025.1487264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":59,"alternative-id":["10.3389\/frph.2025.1487264"],"URL":"https:\/\/doi.org\/10.3389\/frph.2025.1487264","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.27.24312651","asserted-by":"object"}]},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"article-number":"1487264"}}